Massimo Broggini

List of Publications by Year
in descending order

203	6,557	61984 43	82547 72
papers	citations	h-index	g-index

210	210	210	9625
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	LKB1: Can We Target an Hidden Target? Focus on NSCLC. Frontiers in Oncology, 2022, 12, .	2.8	7
2	Single-arm, open label prospective trial to assess prediction of the role ofÂERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open, 2021, 6, 100034.	4.5	0
3	The Crossroads between Host Copper Metabolism and Influenza Infection. International Journal of Molecular Sciences, 2021, 22, 5498.	4.1	6
4	The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. Nature Communications, 2021, 12, 4651.	12.8	22
5	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stressâ€“Based Treatments. Journal of Thoracic Oncology, 2021, 16, 1298-1311.	1.1	9
6	KRAS Targeting and Resistance: Anticipating the Expectable. Journal of Thoracic Oncology, 2021, 16, 1239-1241.	1.1	1
7	miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC. Journal of Thoracic Oncology, 2021, 16, e68-e70.	1.1	0
8	LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. Journal of Thoracic Oncology, 2020, 15, 360-370.	1.1	24
9	Anti-Influenza Effect of Nanosilver in a Mouse Model. Vaccines, 2020, 8, 679.	4.4	8
10	Itâ€™s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?. Cancers, 2020, 12, 3223.	3.7	0
11	Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. Cells, 2020, 9, 1766.	4.1	19
12	Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy. Cancers, 2020, 12, 2022.	3.7	13
13	LKB1ness Dictates ERK Inhibitors Response in NSCLC. Journal of Thoracic Oncology, 2020, 15, e59.	1.1	2
14	Predicting the Role of DNA Polymerase Î² Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. Journal of Clinical Medicine, 2020, 9, 2438.	2.4	2
15	Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. Cancers, 2020, 12, 3846.	3.7	5
16	Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations. Frontiers in Oncology, 2020, 10, 532292.	2.8	6
17	Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines. American Journal of Cancer Research, 2020, 10, 4488-4497.	1.4	0
18	Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers, 2019, 11, 119.	3.7	196

#	Article	IF	Citations
19	Silver Ions as a Tool for Understanding Different Aspects of Copper Metabolism. Nutrients, 2019, 11, 1364.	4.1	38
20	CRISP-R/Cas9 Mediated Deletion of Copper Transport Genes CTR1 and DMT1 in NSCLC Cell Line H1299. Biological and Pharmacological Consequences. Cells, 2019, 8, 322.	4.1	12
21	Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients . Cancer Management and Research, 2019, Volume 11, 10337-10344.	1.9	3
22	Downregulation of class II phosphoinositide 3-kinase PI3K-C2Î² delays cell division and potentiates the effect of docetaxel on cancer cell growth. Journal of Experimental and Clinical Cancer Research, 2019, 38, 472.	8.6	14
23	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clinical Lung Cancer, 2019, 20, e413-e417.	2.6	27
24	Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Scientific Reports, 2018, 8, 948.	3.3	19
25	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	7.0	92
26	Structureâ€“Activity Relationships of Hexahydrocyclopenta[c]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR. ChemMedChem, 2018, 13, 2627-2634.	3.2	23
27	Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. Journal of Experimental and Clinical Cancer Research, 2018, 37, 302.	8.6	27
28	Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells. BMC Cancer, 2018, 18, 1028.	2.6	7
29	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. Journal of Thoracic Oncology, 2018, 13, 1692-1704.	1.1	74
30	Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking. Future Medicinal Chemistry, 2018, 10, 1545-1553.	2.3	21
31	RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clinical Lung Cancer, 2018, 19, e811-e814.	2.6	15
32	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene, 2018, 37, 6463-6476.	5.9	15
33	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	8.6	27
34	Abstract A112: RanBP9 protects cells from genotoxic stress and increased expression is predictive of worse response to platinum in NSCLC patients. , 2018, , .		0
35	Abstract LB-245: Multiple DNA-damage response pathways are modulated by RANBP9 protein in NSCLC. , 2018, , .		0
36	Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models. Translational Oncology, 2017, 10, 153-157.	3.7	9

#	Article	IF	Citations
37	Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. Molecular Cancer, 2017, 16, 97.	19.2	15
38	Probing an Allosteric Pocket of CDK2 with Small Molecules. ChemMedChem, 2017, 12, 33-41.	3.2	21
39	P2.02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors. Journal of Thoracic Oncology, 2017, 12, S2123-S2124.	1.1	0
40	Correlation between clinical outcomes of patients treated within the tailor trial and next-generation sequencing (NGS) results: Analysis of genes associated to KRAS mutations. Annals of Oncology, 2017, 28, ii61.	1.2	1
41	Co-existance of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. Journal of Clinical Oncology, 2017, 35, e20631-e20631.	1.6	0
42	Abstract 2352: Effect of inhibition of cell cycle versus transcription cyclin-dependent kinases (CDKs) in ovarian cancer cells. , 2017, , .		0
43	Abstract 174: Preclinical activity of new liposomal formulation of doxorubicin (TLD-1). , 2017, , .		0
44	Abstract 760: Detection of EGFR T790M mutation by ddPCR in untreated NSCLC patients: Correlation with clinical outcome. , 2017, , .		0
45	Abstract 3739: Comparison of technologies forEGFRanalysis within a subset of a randomized clinical trial. , 2017, , .		2
46	Abstract 508: DNA repair status in a patient derived ovarian cancer xenobank. , 2017, , .		1
47	Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines. PLoS ONE, 2016, 11, e0145647.	2.5	18
48	The 5â€²UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Scientific Reports, 2016, 6, 39217.	3.3	3
49	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. Cancer Treatment Reviews, 2016, 48, 8-19.	7.7	26
50	G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1170-1175.	1.1	5
51	In vivo effect of copper status on cisplatin-induced nephrotoxicity. BioMetals, 2016, 29, 841-849.	4.1	7
52	Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo. Scientific Reports, 2016, 6, 28398.	3.3	29
53	Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX. Translational Oncology, 2016, 9, 458-465.	3.7	9
54	âˆ†Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299. Tumor Biology, 2016, 37, 2015-2021.	1.8	0

#	Article	IF	Citations
55	Class II phosphoinositide 3-kinase C2Î² regulates a novel signaling pathway involved in breast cancer progression. Oncotarget, 2016, 7, 18325-18345.	1.8	25
56	Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget, 2016, 7, 51462-51472.	1.8	21
57	Abstract 226: PI3K pathway inhibition induces a different metabolic response in NSCLC cells harboring WT and G12C mutant KRAS. , 2016, , .		0
58	Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features. , 2016, , .		0
59	Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Scientific Reports, 2015, 5, 16331.	3.3	10
60	Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function. International Journal of Biological Markers, 2015, 30, 275-281.	1.8	3
61	KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget, 2015, 6, 34014-34022.	1.8	68
62	EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncology, The, 2015, 16, 746-748.	10.7	3
63	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Annals of Oncology, 2015, 26, 2079-2084.	1.2	42
64	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Annals of Oncology, 2015, 26, 838-847.	1.2	21
65	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
66	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget, 2015, 6, 30072-30087.	1.8	43
67	Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models. , 2015, , .		0
68	Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models. , 2015, , .		0
69	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data. Journal of Thoracic Disease, 2015, 7, 224-6.	1.4	2
70	Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget, 2014, 5, 4722-4731.	1.8	80
71	Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases. Molecular Cancer, 2014, 13, 238.	19.2	24
72	Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2. Cell Cycle, 2014, 13, 2296-2305.	2.6	48

#	Article	IF	Citations
73	DRAGO (KIAA0247), a New DNA Damageâ€“Responsive, p53-Inducible Gene That Cooperates With p53 as Oncosuppressor. Journal of the National Cancer Institute, 2014, 106, dju053.	6.3	19
74	Brassinin and its derivatives as potential anticancer agents. Toxicology in Vitro, 2014, 28, 909-915.	2.4	31
75	Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells. Tumor Biology, 2014, 35, 9967-9975.	1.8	27
76	Genetic markers for prediction of treatment outcomes in ovarian cancer. Pharmacogenomics Journal, 2014, 14, 401-410.	2.0	16
77	Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer. Current Pharmaceutical Design, 2014, 20, 3933-3943.	1.9	27
78	Abstract 4406: Role of KRAS in modulating the metabolomic profile and the response of NSCLC cells to PI3K/mTOR and AMPK interfering agents. , 2014, , .		0
79	Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma. , 2014, , .		0
80	Abstract 3760: Role of epithelial to mesenchymal transition in response to cisplatin in patient-derived ovarian carcinomas. , 2014, , .		0
81	Abstract 803: A vertical combination strategy hitting multiple steps along the MAPK cascade: Molecular mechanisms of action and putative genetic determinants of synergism. , 2014, , .		0
82	The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. Blood, 2014, 124, 1782-1782.	1.4	1
83	Abstract A54: Studies on the molecular mechanisms responsible for cisplatin resistance associated to KRAS G12C mutation in NSCLC. , 2014, , .		0
84	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncology, The, 2013, 14, 981-988.	10.7	472
85	Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. Cancer Treatment Reviews, 2013, 39, 561-568.	7.7	24
86	To Target or Not to Target, That Is the Question. Journal of Clinical Oncology, 2013, 31, 1254-1254.	1.6	3
87	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METâ€”Letter. Clinical Cancer Research, 2013, 19, 4290-4290.	7.0	12
88	Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Annals of Oncology, 2013, 24, 14-20.	1.2	34
89	Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin. Epigenetics, 2013, 8, 656-665.	2.7	26
90	DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics Journal, 2013, 13, 159-172.	2.0	16

#	Article	IF	Citations
91	Non-hepatic tumors change the activity of genes encoding copper trafficking proteins in the liver. Cancer Biology and Therapy, 2013, 14, 614-624.	3.4	16
92	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Management and Research, 2013, 5, 15.	1.9	4
93	Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes. PLoS ONE, 2013, 8, e66243.	2.5	35
94	Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model. PLoS ONE, 2013, 8, e79101.	2.5	16
95	Abstract 792: DRAGO (KIAA0247), a new p53-regulated antioncogene.. , 2013, , .		0
96	ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. American Journal of Cancer Research, 2013, 3, 221-9.	1.4	11
97	RAS/RAF/MEK Inhibitors in Oncology. Current Medicinal Chemistry, 2012, 19, 1164-1176.	2.4	54
98	Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 2012, 11, 2507-2517.	2.6	110
99	Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle, 2012, 11, 1966-1976.	2.6	43
100	Breast Cancerâ€“Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown. Molecular Cancer Therapeutics, 2012, 11, 214-223.	4.1	58
101	Epithelialâ€“mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treatment Reviews, 2012, 38, 689-697.	7.7	235
102	Serum depletion of holo-ceruloplasmin induced by silver ions in vivo reduces uptake of cisplatin. Journal of Inorganic Biochemistry, 2012, 116, 88-96.	3.5	19
103	TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. Journal of Clinical Oncology, 2012, 30, LBA7501-LBA7501.	1.6	26
104	TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. Journal of Clinical Oncology, 2012, 30, LBA7501-LBA7501.	1.6	13
105	KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. American Journal of Cancer Research, 2012, 2, 298-308.	1.4	7
106	New Omics Information for Clinical Trial Utility in the Primary Setting. Journal of the National Cancer Institute Monographs, 2011, 2011, 128-133.	2.1	4
107	Experimental switching of copper status in laboratory rodents. Journal of Trace Elements in Medicine and Biology, 2011, 25, 27-35.	3.0	15
108	Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Annals of Oncology, 2011, 22, 235-237.	1.2	170

#	Article	IF	Citations
109	Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates. Cancer Research, 2011, 71, 4573-4584.	0.9	68
110	Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 1709-1719.	4.1	67
111	Abstract B77: KRAS mutational status impact progression-free survival of patients treated with platinum-based chemotherapy in NSCLC.. , 2011, , .		1
112	Role of Chk1 in the differentiation program of hematopoietic stem cells. Cellular and Molecular Life Sciences, 2010, 67, 1713-1722.	5.4	6
113	Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecologic Oncology, 2010, 118, 182-188.	1.4	54
114	A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. British Journal of Cancer, 2010, 102, 104-114.	6.4	54
115	Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3â€²,4â€²,5â€²-Trimethoxyflavonol, a Quercetin Analogue. Cancer Prevention Research, 2010, 3, 929-939.	1.5	22
116	Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?. Journal of Clinical Oncology, 2010, 28, e467-e467.	1.6	1
117	PI3K/AKT/mTOR Inhibitors In Ovarian Cancer. Current Medicinal Chemistry, 2010, 17, 4433-4447.	2.4	41
118	Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Molecular Cancer, 2010, 9, 259.	19.2	34
119	Role of Glutathione Transferases in the Mechanism of Brostallicin Activation. Biochemistry, 2010, 49, 226-235.	2.5	16
120	Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and Î²-catenin/Wnt pathways. European Journal of Cancer, 2010, 46, 1679-1691.	2.8	85
121	HtrA2 enhances the apoptotic functions of p73 on bax. Cell Death and Differentiation, 2008, 15, 849-858.	11.2	27
122	Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene, 2008, 27, 1805-1811.	5.9	54
123	Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. European Journal of Cancer, 2008, 44, 131-141.	2.8	28
124	Î”Np63 expression is associated with poor survival in ovarian cancer. Annals of Oncology, 2008, 19, 501-507.	1.2	50
125	Analysis of Gene Expression in Early-Stage Ovarian Cancer. Clinical Cancer Research, 2008, 14, 7850-7860.	7.0	43
126	Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil. Clinical Cancer Research, 2008, 14, 5131-5141.	7.0	42

#	Article	IF	Citations
127	Phospholipase Cî³1 Is Required for Metastasis Development and Progression. Cancer Research, 2008, 68, 10187-10196.	0.9	135
128	KCNA1 and TRPC6 ion channels and NHE1 exchanger operate the biological outcome of HGF/scatter factor in renal tubular cells. Growth Factors, 2007, 25, 382-391.	1.7	22
129	p73: A chiaroscuro gene in cancer. European Journal of Cancer, 2007, 43, 1361-1372.	2.8	37
130	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. Nucleic Acids Research, 2007, 35, 2093-2104.	14.5	123
131	Oct-4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker. Stem Cells, 2007, 25, 1675-1680.	3.2	151
132	In vivo evaluation of the role of DNp73Î± protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. International Journal of Cancer, 2007, 120, 506-513.	5.1	12
133	Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemotherapy and Pharmacology, 2006, 57, 1-6.	2.3	57
134	Questioning the oncogenic role of Î”Np73Î± in different cell lines expressingÂp53Âor not. Cancer Biology and Therapy, 2006, 5, 794-803.	3.4	9
135	Effects of inducible overexpression of DNp73Î± on cancer cell growth and response to treatment in vitro and in vivo. Cell Death and Differentiation, 2005, 12, 805-814.	11.2	18
136	PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth. Clinical Cancer Research, 2005, 11, 6835-6839.	7.0	134
137	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Molecular Cancer Therapeutics, 2005, 4, 715-725.	4.1	27
138	Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs. Clinical Cancer Research, 2005, 11, 4348-4356.	7.0	57
139	Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. Cancer Research, 2005, 65, 8339-8349.	0.9	126
140	DNA mirror groove-binding agents. Drugs of the Future, 2005, 30, 301.	0.1	2
141	Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53. Cell Cycle, 2004, 3, 1175-1179.	2.6	68
142	Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene, 2004, 23, 1754-1765.	5.9	89
143	Improving the selectivity of cancer treatments by interfering with cell response pathways. European Journal of Cancer, 2004, 40, 2550-2559.	2.8	25
144	Brostallicin: a new concept in minor groove DNA binder development. Anti-Cancer Drugs, 2004, 15, 1-6.	1.4	30

#	Article	IF	Citations
145	Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle, 2004, 3, 1177-81.	2.6	35
146	Effect of Aplidin in acute lymphoblastic leukaemia cells. British Journal of Cancer, 2003, 89, 763-773.	6.4	52
147	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	7.2	142
148	DNA damage induces transcriptional activation of p73 by removing C-EBPÂ repression on E2F1. Nucleic Acids Research, 2003, 31, 6624-6632.	14.5	29
149	Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle, 2003, 2, 604-9.	2.6	23
150	Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clinical Cancer Research, 2003, 9, 5402-8.	7.0	22
151	Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. International Review of Cytology, 2002, 219, 157-198.	6.2	8
152	Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Research, 2002, 62, 2332-6.	0.9	45
153	Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation. Neoplasia, 2001, 3, 10-16.	5.3	73
154	Development of distamycin-related DNA binding anticancer drugs. Expert Opinion on Investigational Drugs, 2001, 10, 1703-1714.	4.1	35
155	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	5.9	51
156	DNA Damage Induces p53-dependent Down-regulation of hCHK1. Journal of Biological Chemistry, 2001, 276, 10641-10645.	3.4	17
157	Novel functional PI 3â€kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB Journal, 2000, 14, 1179-1187.	0.5	73
158	Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 6780-6784.	7.1	186
159	Driving p53 Response to Bax Activation Greatly Enhances Sensitivity to Taxol by Inducing Massive Apoptosis. Neoplasia, 2000, 2, 202-207.	5.3	22
160	Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAluâ€" Polymerase Chain Reaction. Leukemia and Lymphoma, 2000, 38, 605-610.	1.3	2
161	Allelic expression of p73 in human ovarian cancers. Annals of Oncology, 1999, 10, 949-953.	1.2	12
162	Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. British Journal of Cancer, 1999, 80, 338-343.	6.4	39

#	Article	IF	Citations
163	Î±-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. British Journal of Cancer, 1999, 80, 991-997.	6.4	20
164	P53-independent caspase-mediated apoptosis in human leukaemic cells is induced by a DNA minor groove binder with antineoplastic activity. Apoptosis: an International Journal on Programmed Cell Death, 1999, 4, 39-45.	4.9	11
165	CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes and Cancer, 1999, 26, 176-180.	2.8	82
166	Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. Experimental Cell Research, 1998, 241, 96-101.	2.6	81
167	DNA-topoisomerase I activity and content in epithelial ovarian cancer. Annals of Oncology, 1998, 9, 313-318.	1.2	15
168	hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis, 1998, 19, 691-694.	2.8	14
169	Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer. Gynecologic Oncology, 1997, 65, 130-137.	1.4	53
170	Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53. , 1997, 72, 155-159.		21
171	Changes in Cyclins and Cyclin-Dependent Kinases Induced by DNA Damaging Agents in a Human Ovarian Cancer Cell Line Expressing Mutated or Wild-Type P53. Experimental Cell Research, 1996, 227, 380-385.	2.6	14
172	p53 Regulates the Minimal Promoter of the Human Topoisomerase IIÂ Gene. Nucleic Acids Research, 1996, 24, 4464-4470.	14.5	83
173	Characterization of a protein recognizing minor groove binders-damaged DNA. Nucleic Acids Research, 1996, 24, 4227-4233.	14.5	5
174	Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. British Journal of Cancer, 1995, 71, 505-511.	6.4	18
175	DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Research, 1995, 23, 81-87.	14.5	92
176	Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Research, 1994, 22, 1012-1017.	14.5	52
177	L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. British Journal of Cancer, 1994, 69, 315-319.	6.4	10
178	Establishment of l1210 leukemia cells resistant to the distamycin-a derivative (FCE 24517): Characterization and cross-resistance studies. International Journal of Cancer, 1993, 53, 308-314.	5.1	18
179	Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE) Tj ETQq1 1 0.784314 rgBT /Overlock	6.4	9
180	Differential inhibition of the DNA binding of transcription factors NFxB and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications. Carcinogenesis, 1993, 14, 1963-1967.	2.8	13

#	Article	IF	Citations
181	Sequence and Gene-Specific Drugs. , 1992, , 5-11.		3
182	Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. British Journal of Cancer, 1991, 64, 288-292.	6.4	8
183	The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961. Journal of Antimicrobial Chemotherapy, 1991, 27, 687-689.	3.0	1
184	DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate). British Journal of Cancer, 1990, 61, 285-289.	6.4	8
185	Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Research, 1989, 17, 1051-1059.	14.5	99
186	DNA interstrand cross-links induced by cis-dichlorodiammine platinum in ovarian cancer cells growing in primary culture. Biochemical Pharmacology, 1988, 37, 1835-1836.	4.4	0
187	Early DNA damage induced in cells exposed to N10-propargyl 5,8-dideazafolic acid (CB 3717) or methotrexate. Biochemical Pharmacology, 1988, 37, 1875-1876.	4.4	3
188	Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. Biochemical Pharmacology, 1988, 37, 4423-4431.	4.4	22
189	Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. European Journal of Cancer & Clinical Oncology, 1986, 22, 173-179.	0.7	18
190	In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. Cancer Chemotherapy and Pharmacology, 1986, 16, 125-8.	2.3	7
191	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney International, 1986, 30, 488-496.	5.2	158
192	Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite. Chemico-Biological Interactions, 1985, 55, 215-224.	4.0	10
193	Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma. Biochemical Pharmacology, 1984, 33, 2715-2722.	4.4	2
194	Central side effects of pentamethylmelamine: Biochemical and behavioural studies. Biochemical Pharmacology, 1984, 33, 4011-4015.	4.4	1
195	Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. Cancer Chemotherapy and Pharmacology, 1983, 10, 208-11.	2.3	16
196	Subcellular distribution of adriamycin in the liver and tumor of 3LL-bearing mice. European Journal of Cancer & Clinical Oncology, 1983, 19, 419-426.	0.7	5
197	Routes of elimination of hexamethylmelamine and pentamethylmelamine in the rat. Xenobiotica, 1982, 12, 315-321.	1.1	5
198	Studies of the mode of action of antitumour triazenes and triazinesâ€"III. Metabolism studies on hexamethylmelamine. Biochemical Pharmacology, 1982, 31, 625-631.	4.4	14

#	Article	IF	Citations
199	Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. Cancer Chemotherapy and Pharmacology, 1982, 7, 127-31.	2.3	26
200	Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit. European Journal of Cancer & Clinical Oncology, 1981, 17, 1089-1096.	0.7	9
201	Diferential adriamycinÂ® istribution to blood components. European Journal of Drug Metabolism and Pharmacokinetics, 1981, 6, 115-122.	1.6	13
202	Influence of tumor on adriamycin concentration in blood cells. Cancer Chemotherapy and Pharmacology, 1980, 4, 209-12.	2.3	13
203	Importance of the presence of necrosis in studying drug distribution within tumor tissue. European Journal of Drug Metabolism and Pharmacokinetics, 1977, 2, 63-67.	1.6	8